Troglitazone

Comprehensive Therapy

Volumn 23, Issue 9, 1997, Pages 560-562

  Santiago, Julio V ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; THIAZOLE DERIVATIVE; TROGLITAZONE;

HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

CHROMANS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031203282     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Saltial AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
2. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of a new oral hypoglycémie agent CS-045 in NIDDM subjects. Diabetes Care. 1992:15:193-203.
3. Driscoll J, Ghazzi M, Ferez J, Huang S, Whitcomb R. A 96-week follow-up on cardiac safety in patients with type 2 diabetes treated with troglitazone. Diabetes. 1997;46(suppl 1):P149A, 0574.
4. Raskin P, Graveline JF. Efficacy of troglitazone in combination with insulin in NIDDM. Diabetes. 1997;46(suppl 1):P44A, 0170.
5. Ghazzi M, Radke-Mitchell L, Umable T, Whitcomb R. Troglitazone improves glycémie control in patients with type 2 diabetes who are not optimally controlled on sulfonylurea. Diabetes. 1997;46(suppl 1):P44A, 0169.
6. Inzucchi SE, Maggs DG, Spollet GR, et al. Efficacy and metabolic effects of troglitazone and metformin in NIDDM. Diabetes. 1997;46(suppl 1):P34A, 0134.